UK vows to speed up drug review in return for 2% sales cap 27-Nov-2018 By Ben Hargreaves UK government and ABPI have agreed a deal to limit branded drug sales growth to 2%, potentially reducing the cost of medicine by £930m.
MHRA and EMA divorce process continues ahead of Brexit deadline 04-Sep-2018 By Ben Hargreaves It has been revealed that the EMA is awarding significantly fewer contracts to evaluate the application of new drugs to the MHRA, as the Brexit deadline nears.